Titan Pharmaceuticals Stock

TTNP

US8883147055

Market Closed - Nasdaq Other stock markets 23:00:00 07/08/2026 +03			5-day change	1st Jan Change
0.8001 ^USD	+4.59%		+16.46%	-82.64%

04/10/25	Titan Pharmaceuticals announces closing of merger with Black Titan Corporation	RE
01/10/25	Titan Pharmaceuticals, Inc. Appoints Chay Weei Jye as the Sole Director and Acting Secretary, Effective October 1, 2025	CI

Valuation: Titan Pharmaceuticals

Market Cap	6.13M 5.3M 4.95M 4.54M 8.55M 584M 8.68M 58.12M 22.81M 293M 23.03M 22.52M 967M	P/E 2023	-1.11x	P/E 2024	-0.62x
Enterprise Value	3.3M 2.86M 2.67M 2.45M 4.6M 314M 4.67M 31.29M 12.28M 157M 12.4M 12.13M 521M	EV / Sales 2023	0.11x	EV / Sales 2024	-
Free-Float	-	Yield 2023 *	-	Yield 2024	-

* Estimated data More valuation ratios

Latest news : Titan Pharmaceuticals

04/10/25	Titan Pharmaceuticals announces closing of merger with Black Titan Corporation	RE
01/10/25	Titan Pharmaceuticals, Inc. Appoints Chay Weei Jye as the Sole Director and Acting Secretary, Effective October 1, 2025	CI
01/10/25	Titan Pharmaceuticals, Inc.(NasdaqCM:TTNP) dropped from NASDAQ Composite Index	CI
01/10/25	Ke Sdn. Bhd. completed the acquisition of Titan Pharmaceuticals, Inc. in a reverse merger transaction.	CI
14/08/25	Titan Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
27/06/25	Titan Pharmaceuticals, Inc. announced that it has received $0.6 million in funding from Blue Harbour Asset Management L.L.C	CI
24/06/25	Titan Pharmaceuticals, Inc. announced that it expects to receive $0.6 million in funding from Blue Harbour Asset Management L.L.C	CI
14/05/25	Titan Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
11/04/25	Titan Pharmaceuticals Announces $1 Million Private Placement Of Convertible Preferred Stock	RE
11/04/25	Titan Pharmaceuticals, Inc. announced that it has received $1 million in funding	CI
01/04/25	Titan Pharmaceuticals, Inc. Appoints Gabriel Loh as an Independent Director and Member of the Audit Committee	CI
29/03/25	Titan Pharmaceuticals, Inc. announced that it expects to receive $1 million in funding	CI
20/03/25	Titan Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI

More news

Analysts' recommendations: Titan Pharmaceuticals

26/05/22	Maxim Downgrades Titan Pharmaceuticals to Hold From Buy	MT
18/02/21	TITAN PHARMACEUTICALS : Maxim Group Upgrades Titan Pharmaceuticals to Buy From Hold, $11 Price Target	MT

More recommendations

Press Releases: Titan Pharmaceuticals

15/08/25	Titan Pharmaceuticals: Q2 Earnings Snapshot	AQ
06/08/25	TITAN PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Titan Pharmaceuticals, Inc. - TTNP	BU
27/06/25	Titan Pharmaceuticals Announces $600,000 Private Placement of Convertible Preferred Stock	AQ
03/06/25	Titan Pharmaceuticals Announces Filing of Registration Statement for Proposed Business Combination with TalenTec Sdn. Bhd.	AQ
15/05/25	Titan Pharmaceuticals: Q1 Earnings Snapshot	AQ

More press releases

Titan Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on developing therapeutics utilizing the proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. ProNeura offers continuous drug delivery and consists of a small, semi-rigid, flexible implant made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The resulting product is a solid matrix implant that is placed subdermally, normally in the inside part of the upper arm, in a brief procedure using a local anesthetic and is removed in a similar manner at the end of the treatment period. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus. Its product development programs are in non-clinical stages of development.

Employees

Sector

More about the company

Quotes

Date	Price	Change	Volume
07/08/26	$0.8001	+4.59%	18,498
06/08/26	$0.7650	-0.20%	13,764
05/08/26	$0.7665	+3.00%	14,897
04/08/26	$0.7442	+1.14%	5,020
03/08/26	$0.7358	+7.10%	11,733

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

1 year	0.76	5.34
3 years	0	14.8
5 years	0	47.6
10 years	0	23,040.03

	2023	2024
Net sales	184K 159K 149K 136K 256K 17.51M 261K 1.74M 684K 8.78M 691K 676K 29.02M	-
Net income	-5.57M -4.82M -4.5M -4.13M -7.76M -530M -7.89M -52.78M -20.72M -266M -20.91M -20.45M -878M	-4.71M -4.07M -3.8M -3.49M -6.56M -448M -6.66M -44.6M -17.51M -224M -17.67M -17.29M -742M
Net Debt	-6.2M -5.36M -5M -4.59M -8.63M -590M -8.77M -58.71M -23.04M -296M -23.26M -22.75M -977M	-2.83M -2.45M -2.29M -2.1M -3.95M -269M -4.01M -26.83M -10.53M -135M -10.63M -10.4M -446M

Titan Pharmaceuticals Stock

Stocks

TTNP

US8883147055

Valuation: Titan Pharmaceuticals

Chart: Titan Pharmaceuticals

Latest news : Titan Pharmaceuticals

Analysts' recommendations: Titan Pharmaceuticals

Press Releases: Titan Pharmaceuticals

Quotes and Performance

Course Extremes

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	+4.59%
Current month	-82.64%
Current year	-82.64%